CNS-related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team In Preparation For Phase 3 Trial
CNS-RELATED EDEMA COMPANY REMEDY PHARMACEUTICALS STRENGTHENS LEADERSHIP TEAM IN PREPARATION FOR PHASE 3 TRIAL
NEW YORK, New York, January 5, 2016 — Remedy Pharmaceuticals, a clinical stage pharmaceutical company focused on the development and commercialization of an innovative central nervous system drug, CIRARA™, announced today that the Company strengthened its leadership team with the appointment of Ann Tunstall as Vice President of Regulatory and Operational Affairs, and Alan Cutler as Vice President of Chemistry Manufacturing and Controls.
"We’re excited to have Ann and Alan join our executive team,” commented Sven Jacobson, CEO of Remedy Pharmaceuticals. “They bring a wealth of experience and tremendous knowledge, which we believe will be a great asset to the company as we move closer to initiating our Phase 3 trial targeting brain swelling following severe stroke. We also look forward to their contributions as we accelerate our clinical trial efforts in other CNS conditions where swelling is an important determinant of outcome such as spinal cord injury, traumatic brain injury and subarachnoid hemorrhage.”
Ann Tunstall has 25 years of experience in the healthcare industry, identifying and implementing effective regulatory and clinical development strategies for novel and repositioned pharmaceuticals and combination products. Her experience covers a wide range of therapeutic areas, with a particular focus on neurological indications. Dr. Tunstall has a Ph.D. in Biomedical Engineering from the University of Texas Southwestern Medical Center, an M.S. in Material Science from Duke University, and a B.S. in Biomedical Engineering from Duke University.
Alan Cutler has over two decades of successful product research and development and commercialization experience. Previously, he held the position of Vice President of Research and Development and Chief Scientific Officer at Three Rivers Pharmaceuticals, LLC (now Kadmon Pharmaceuticals, LLC), Senior Director of Research and Development at Ascend Therapeutics, and Senior Project Leader at DSM Pharmaceuticals Inc. Dr. Cutler also spent 18 years in various R&D and global project-leadership positions at 3M. He received his Bachelor’s Degree in Chemistry from SUNY at Buffalo and his Doctoral Degree from the University of East Anglia’s School of Chemical Sciences.
CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels. Sur1-Trpm4 channels are upregulated following ischemia and open due to ATP depletion resulting in sodium influx, which is followed by water that leads to cell swelling, damage and death. Dysfunction of endothelial cells through this mechanism results in blood brain barrier disruption which allows fluids to cross into the brain, i.e., brain swelling. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses a proprietary, patented MPD™ technology for drug delivery. CIRARA is an investigational drug and is not approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals is a privately-held, clinical stage pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, which can occur in ischemic stroke, traumatic brain injury, subarachnoid hemorrhage, spinal cord injury, intracerebral hemorrhage, and following neurosurgery, as well as in other ischemic and traumatic CNS injuries.
Contact: Sven Jacobson
212-586-2226 x 225